The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has been Downgraded to Sell from Neutral by B. Riley FBR in its latest research note that was published on July 16. ADMP was given a price target of $1.10 by B. Riley FBR, with other Wall Street analysts also giving their reports regarding the stock. B. Riley FBR analysts have downgraded their rating of ADMP stock from Buy to Neutral in a separate flash note to investors on November 12. Analysts at Maxim Group are sticking to their Buy recommendation. However, on May 11, they lifted target price for these shares to $10 from $5.Analysts at Maxim Group, made their first call for the stock with a Buy rating, according to a research note that dated back to May 11.
Adamis Pharmaceuticals Corporation, which has current market capitalization of above $50 Million, published its last quarter earnings on June 30, 2019.
ADMP surged by $0.01 during the normal trading session on Thursday and reaching a high of $0.91 during the day while it closed the day at $0.85. The Adamis stock had a low trading volume of 0.93 million shares on that day, which is low compared to the average daily volume of 615.00M shares. ADMP has also gained 16.74% of its value over the past 7 days. However, the stock has declined by 42.11% in the 3 months of the year. Over the past six months meanwhile, it has lost 69.82% while it has lost 62.18% year-on date. Let us now take a look at the stock’s potential support and resistance levels. The publicly traded company was seen to have slipped by -45.8% from its 3 months high price. However, taking another look at ADMP will indicate that it is trading +21.57% away from its 90-day low. Looking at the bigger picture, the Adamis Pharmaceuticals Corporation stock has dropped by -79.98% from its 52-week high while it has surged by +21.57% from its 52-week low price.
On August 19, 2019 Moss Ronald B., Chief Medical Officer sold 8383 shares of the company. The average price for that transaction was $1.06 per share, which meant that Moss Ronald B. earned $8885.98 selling the stocks. The sale was made public, with the document of the transaction filed with the SEC. Another insider trading occurred, with SVP and Chief Business Officer, Marguglio David J. selling 8109 shares of this stock on August 19, 2019. The average selling price for the stock was $1.1 per share, with the sold stock accruing $8919.9. Following this transaction, the SVP and Chief Business Officer Marguglio David J. now holds 169110 shares of the company, which is worth around $152199.
Adamis has around 4 Billion cash on their books at the moment. This figure will have to be compared and looked into, with their current liabilities standing at $11 Billion. The Adamis stock is bringing in revenue of over 12 months, which is roughly 6 Billion. Despite all that, Adamis Pharmaceuticals Corporation is seeing things progressing very much as their y-o-y quarterly revenue surged by 47.03%.
Looking at the stock’s Technical analysis information over the past 50 days shows that its Raw Stochastic average stood at 17.36%. This figure is worse than the company’s 20-day Raw Stochastic average which currently stands at 35.95%. Over the past 20 days, Adamis’s Stochastic %K stood at 33.06% while its Stochastic %D was revealed to be 23.61%.